CVS Offering Possible 14.16% Return Over the Next 18 Calendar Days

CVS's most recent trend suggests a bearish bias. One trading opportunity on CVS is a Bear Call Spread using a strike $67.50 short call and a strike $72.50 long call offers a potential 14.16% return on risk over the next 18 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $67.50 by expiration. The full premium credit of $0.62 would be kept by the premium seller. The risk of $4.38 would be incurred if the stock rose above the $72.50 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for CVS is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for CVS is bearish.

The RSI indicator is below 20 which suggests that the stock is in oversold territory.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for CVS

Final Glance: Drugstore companies
Tue, 04 Feb 2014 23:06:23 GMT
AP – Shares of some top drugstore companies were up at the close of trading: CVSCaremark rose $.32 or .5 percent, to $66.11. Rite Aid rose $.01 or .2 percent, to $5.34. Walgreen rose $.38 or .7 percent, to …

CVS Caremark Awarded Pharmacy Benefit Management Institute Rx Benefit Innovation Award for New Specialty Connect Program
Tue, 04 Feb 2014 19:13:00 GMT
PR Newswire – WOONSOCKET, R.I., Feb. 4, 2014 /PRNewswire/ — CVS Caremark (CVS) was today awarded the 2014 Rx Benefit Innovation Award by the Pharmacy Benefit Management Institute (PBMI). The award recognizes the company's new Specialty Connect program, which was developed by CVS Caremark to improve access, quality of care and convenience for specialty pharmacy patients. While one-third of patients currently attempt to fill their specialty prescriptions at a local retail pharmacy because of the convenience and familiarity the location offers, 15-25 percent are turned away without the medication or direction on where to go for help, resulting in delayed or abandoned treatment. The Specialty Connect program leverages CVS Caremark's unique retail and specialty pharmacy resources to help patients access their medications locally while still receiving dedicated clinical management services from experts in each therapeutic area. Through this program, CVS/pharmacy locations can accept specialty prescriptions and patients have the choice of in-store pickup or delivery to their home or office. CVS Caremark Specialty Pharmacy CareTeam pharmacists and nurse practitioners provide ongoing clinical support and counseling by phone. In addition, value-added retail pharmacy services (e.g., text message prescription reminders, prescription status information and online prescription refill tools) are available to help patients stay on therapy and manage their condition.

Glaxo’s Advair Loses U.S. Market Share to Astra, Merck
Tue, 04 Feb 2014 15:34:17 GMT
Bloomberg – GlaxoSmithKline Plc (GSK) ’s best-selling Advair drug for smokers’ cough and asthma is losing U.S. market share to products from AstraZeneca Plc (AZN) and Merck & Co. after the country’s largest pharmacy-benefits manager dropped Advair from its 2014 list of reimbursed medicines. Advair’s share of the inhaled corticosteroid and long-acting bronchodilator market fell to 61.6 percent for the week ended Jan. 24, compared with 68.4 percent for the week ended Sept. 6, according to the most recent data compiled by Bloomberg and Symphony Health Solutions. Growing demand for AstraZeneca’s Symbicort, which has a market share of 30 percent, and Merck’s Dulera, with an 8.4 percent share, have eaten into Advair sales, which were 2.5 billion pounds ($4.1 billion) in the U.S. in 2012.

Early Glance: Drugstore companies
Tue, 04 Feb 2014 15:32:44 GMT
AP – Shares of some top drugstore companies are up at 10 a.m.: CVSCaremark rose $.54 or .8 percent, to $66.33. Rite Aid unchanged at $5.33. Walgreen rose $.36 or .6 percent, to $55.93.

Walgreen (WAG) Sues Rite Aid (RAD), CVS Caremark (CVS) and Shopko Over Express Refill System
Mon, 03 Feb 2014 20:27:00 GMT
TheStreet – Walgreen (WAG) has filed a lawsuit against Rite Aid (RAD), CVS Caremark (CVS) and Shopko Stores to claim that the competitors are using Walgreen's new patent on technology for refilling prescriptions with …

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.